Proceeds Will Carry First Drug Candidates Into Clinical Trials. Existing And New Investors Participate Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the...
Read More »Exosome Diagnostics Completes $30 Million Series C Financing
Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners. Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD ...
Read More »Grail plans to raise $1 billion for liquid biopsy clinical trials
Illumina, Inc. (NASDAQ: ILMN), today announced that GRAIL has received indications of interest to invest approximately $1B for its Series B financing, primarily from undisclosed private and strategic investors. GRAIL intends to raise additional capital in the Series B financing ...
Read More »Liquid biopsy company Guardant Health draws $100 million to sleuth out cancers
from San Francisco Business Times by Ron Leuty Guardant Health Inc. snagged nearly $100 million in funding from OrbiMed Advisors and others to aggressively expand its commercial and scientific work as competitors jump into the liquid biopsy market. The Redwood ...
Read More »Exosome Diagnostics Completes $60 Million Series B Financing
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies, today announced the final close of its $60 million Series ...
Read More »